Overview

MTX and Steroid for III-IV aGVHD Treatment

Status:
Recruiting

Trial end date:
2022-09-30

Target enrollment:

Participant gender:

Summary

The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid treatment for grade III-IV acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Phase:

Phase 2

Details

Lead Sponsor:

Peking University People's Hospital

Treatments:

Methotrexate